Girentuximab
Encyclopedia
Girentuximab is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma
.
Girentuximab was developed by Wilex AG.
Renal cell carcinoma
Renal cell carcinoma is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that filter the blood and remove waste products. RCC is the most common type of kidney cancer in adults, responsible for approximately 80% of cases...
.
Girentuximab was developed by Wilex AG.